Redhill Biopharma RDHL

NAS: RDHL | ISIN: US7574681034   26/04/2024
0,428 USD (+2,84%)
(+2,84%)   26/04/2024

24 april 2024 · RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study · Persbericht

8 april 2024 · RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights · Persbericht

2 april 2024 · RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price · Persbericht

11 maart 2024 · RedHill Announces New USPTO Patent Covering Talicia® Through 2034 · Persbericht

5 maart 2024 · RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs · Persbericht

20 februari 2024 · RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication · Persbericht

26 januari 2024 · RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering · Persbericht

25 januari 2024 · RedHill Biopharma Announces $8 Million Registered Direct Offering · Persbericht

25 januari 2024 · RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 · Persbericht

20 december 2023 · RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola · Persbericht

12 december 2023 · RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

4 december 2023 · RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study · Persbericht

17 oktober 2023 · Thinking about buying stock in Momentus Inc, Secoo Holding, RedHill Biopharma, Aldeyra Therapeutics, or Mereo BioPharma Group? · Persbericht

4 oktober 2023 · Thinking about buying stock in ALX Oncology Holdings, RedHill Biopharma, Freeline Therapeutics Holdings, Terawulf, or I-Mab? · Persbericht

3 oktober 2023 · RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study · Persbericht

18 september 2023 · RedHill Announces FDA sNDA Approval for Talicia® · Persbericht

5 september 2023 · RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®) · Persbericht

17 augustus 2023 · RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights · Persbericht

1 augustus 2023 · RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. · Persbericht

31 juli 2023 · RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA · Persbericht

Mijn selecties